Summary: Aegon Ltd.

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • According to MSCI, the company's ESG score for its industry is good.

Highlights: Aegon Ltd.

  • The company's profit outlook over the next few years is a strong asset.
  • The company is one of the best yield companies with high dividend expectations.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses: Aegon Ltd.

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's earnings releases usually do not meet expectations.

Ratings Chart: Aegon Ltd.

Source: Surperformance

ESG chart: Aegon Ltd.

Source: MSCI

Add to a list
Fundamentals Valuation Revisions of Fundamental Estimates Capi.($)
56.97B
Average 56.97B
Weighted average by Cap.
See all sector ratings
Investor
Trader
ESG MSCI
AA

Financials

Sales growth
EPS Growth
Profitability
Net margin
Financial Health
-

Valuation

P/E ratio
EV/REVENUE
EV/EBITDA
-
PBR
Yield

Revisions

1 year Revenue revision
4 months Revenue revision
1 months Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analysts' recommendations
4m Revision of opinion
Potential Price Target
4m Target Price Revision
12m Target Price Revision

Business Predictability

Earnings quality
Analyst Coverag
Divergence of analysts' recommendations
Divergence of Target Price
Divergence of analysts' opinions

ESG

Environment
Social
Governance
Controversy
ESG: Ethical controversies
ESG: Human rights controversies
ESG: Tax subsidies controversies
Sharia compliant

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes